Der Gynäkologe

, Volume 39, Issue 3, pp 239–250

Das Ovarialkarzinom

Herausforderung für Arzt und Patientin
Weiterbildung · Zertifizierte Fortbildung

Zusammenfassung

Obwohl das Ovarialkarzinom als maligner, epithelialer Tumor mit etwa 8000 Neuerkrankungen pro Jahr in Deutschland nur die 7. häufigste Malignomerkrankung bei der Frau ist, steht es bei allen Todesursachen an 4. Stelle und ist somit in Relation zur Anzahl der Erkrankten die häufigste gynäkologische Krebstodesursache. Diese Zahlen untermauern, trotz der relativ geringen Inzidenz der Erkrankung, die hohe gesundheitspolitische Bedeutung. In letzter Zeit hat es zahlreiche neue Erkenntnisse in der Primär- und Rezidivtherapie der Erkrankung gegeben. Die Umsetzung dieser in nationalen und internationalen Standards und Leitlinien implementierten neuen Entwicklungen in den klinischen Alltag ist zur Verbesserung der Situation der Betroffenen dringend erforderlich, nicht zuletzt da die Therapie des Ovarialkarzinoms — und damit die Prognose der Patientinnen — in Deutschland im Vergleich mit anderen europäischen Ländern schlechter ist.

Schlüsselwörter

Ovarialkarzinom Operation Chemotherapie Rezidiv 

Ovarian cancer

A challenge for physician and patient

Abstract

Although ovarian cancer in the form of a malignant epithelial tumor, with about 8,000 new cases per year in Germany, represents only the seventh most common malignant tumor in women, it is the fourth most common cause of death. In relation to the number of affected women, it is therefore the most common gynecologic cause of death due to cancer. Despite the relatively low incidence of the disease, these figures emphasize its major importance for the health sector. Recently, numerous new findings have emerged on the treatment of primary and recurrent disease. The implementation of these new developments already incorporated in national and international standards and guidelines into clinical practice, is essential for the improvement of the patients’ situation, given the fact that compared to other European countries, treatment of ovarian cancer, and thus also its prognosis, in Germany is worsi.

Keywords

Ovarian Cancer Surgery Chemotherapy Recurrence 

Literatur

  1. 1.
    Armstrong DK, Bundy B, Wenzel L et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43CrossRefPubMedGoogle Scholar
  2. 2.
    Bell DA, Longacre TA, Prat J et al. (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35: 934–948CrossRefPubMedGoogle Scholar
  3. 3.
    Benedetti-Panici PB, Maggioni A, Hacker N et al. (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97: 560–566CrossRefGoogle Scholar
  4. 4.
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–1259CrossRefPubMedGoogle Scholar
  5. 5.
    Du Bois A, Lück HJ, Meier W et al. (2003) A randomized clinical trial of Cisplatin/Paclitaxel versus Caboplatin/Paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320–1329CrossRefPubMedGoogle Scholar
  6. 6.
    ICON, International Collaborative Ovarian Neoplasm Collaborators (2003) International Collaborative Ovarian Neoplasm Trial-1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95: 125–132CrossRefGoogle Scholar
  7. 7.
    ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099–2106CrossRefGoogle Scholar
  8. 8.
    Kommission Ovar der AGO (2005) Ovarialkarzinom State of the Art. Juni 2005. CD-ROM (ISBN 3-00-016495-2)Google Scholar
  9. 9.
    Lecuru F, Desfeux P, Camatte S, Bissery A, Robin F, Blanc B, Querleu D (2004) Stage I ovarian cancer: comparison of laparoscopy and laparotomy on staging and survival. Eur J Gynaecol Oncol 25: 571–576PubMedGoogle Scholar
  10. 10.
    Mateo R, Singh G, Jabbour N, Palmer S, Genyk Y, Roman L (2005) Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors. Gynecol Oncol 97: 266–270CrossRefPubMedGoogle Scholar
  11. 11.
    Negishi H, Takeda M, Fujimoto T et al. (2004) Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol Oncol 94: 161–166CrossRefPubMedGoogle Scholar
  12. 12.
    Pfisterer J, Plante M, Vergote I, du Bois A, Eisenhauer E, for the AGO-OVAR, NCIC CTG & EORTC GCG (2005) Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 15 [Suppl 1]:36–41Google Scholar
  13. 13.
    Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–2497CrossRefPubMedGoogle Scholar
  14. 14.
    Seidman JD, Soslow RA, Vang R et al. (2004) Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 35: 918–933CrossRefPubMedGoogle Scholar
  15. 15.
    Trimbos JB, Vergote I, Bolis G et al. (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113–125CrossRefPubMedGoogle Scholar
  16. 16.
    Vergote I, De Brabanter J, Fyles A et al. (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357: 176–182CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Klinik für Gynäkologie und Geburtshilfe Campus KielUniversitätsklinikum Schleswig-HolsteinDeutschland
  2. 2.Frauenklinik der Technischen Universität MünchenDeutschland
  3. 3.Klinik für Gynäkologie und Gynäkologische OnkologieDr.-Horst-Schmidt-Klinik GmbHWiesbaden
  4. 4.Klinik für Gynäkologie und Geburtshilfe Campus KielUniversitätsklinikum Schleswig-HolsteinKielDeutschland

Personalised recommendations